The anti-PD-1 monotherapy demonstrated significant efficacy, with nivolumab achieving a three-year OS rate of 51.2% compared to 21.6% for dacarbazine in BRAF wild-type melanoma [18]. This evidence concerns the gene BRAF and melanoma.